Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness, safety, and tolerability of combining adagrasib with pembrolizumab and platinum-based chemotherapy compared to a placebo combined with pembrolizumab and platinum-based chemotherapy. This study includes participants with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC who have a KRAS G12C mutation. It is a phase 3, randomized, double-blind trial sponsored by Mirati Therapeutics Inc. Participants will receive either adagrasib plus pembrolizumab plus platinum-doublet chemotherapy or placebo plus pembrolizumab plus platinum-doublet chemotherapy. The chemotherapy agents include carboplatin, pemetrexed, or cisplatin, administered at specified doses on specified days. The study uses a parallel assignment model with quadruple masking. The treatment phase involves these medications, with ongoing monitoring for up to seven years to assess progression-free survival and overall survival. During the trial, participants will undergo regular imaging scans such as CT or MRI to measure disease response according to RECIST v1.1 criteria. Researchers will track outcomes including tumor progression, overall response, duration of response, safety events like adverse and serious adverse events, and quality of life using questionnaires. Safety monitoring continues up to 90 days after the last dose. The total study period may last up to seven years to collect long-term survival and symptom data.